Identification of individual cancer-specific somatic mutations for neoantigen-based immunotherapy of lung cancer

Journal of Thoracic Oncology

Volumn 11, Issue 3, 2016, Pages 324-333

  Karasaki, Takahiro ^a   Nagayama, Kazuhiro ^a   Kawashima, Mitsuaki ^a   Hiyama, Noriko ^a   Murayama, Tomonori ^a   Kuwano, Hideki ^a   Nitadori, Jun Ichi ^a   Anraku, Masaki ^a   Sato, Masaaki ^a   Miyai, Manami ^b,c   Hosoi, Akihiro ^b,c   Matsushita, Hirokazu ^b   Kikugawa, Shingo ^d   Matoba, Ryo ^d   Ohara, Osamu ^e   Kakimi, Kazuhiro ^b   Nakajima, Jun ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^c University of Tokyo   (Japan)

^d DNA CHIP RESEARCH INC   (Japan)

^e KAZUSA DNA RESEARCH INSTITUTE   (Japan)

Author keywords

Exome; Genetic data bank; Immunotherapy; Missense mutation; Neoantigen

Indexed keywords

ANTIGEN; ANTINEOPLASTIC AGENT; HLA ANTIGEN; POTENTIAL NEOANTIGEN; UNCLASSIFIED DRUG; CANCER VACCINE; HLA ANTIGEN CLASS 1; TUMOR ANTIGEN;

ADULT; AGED; ALLELE; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; EXOME; FEMALE; GENE SEQUENCE; HUMAN; LUNG ADENOCARCINOMA; MALE; MISSENSE MUTATION; PERSONALIZED MEDICINE; PRIORITY JOURNAL; SOMATIC MUTATION; SQUAMOUS CELL LUNG CARCINOMA; VERY ELDERLY; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; LUNG TUMOR; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROCEDURES;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANTIGENS, NEOPLASM; CANCER VACCINES; EXOME; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MUTATION, MISSENSE; PRECISION MEDICINE;

EID: 84962607504     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2015.11.006     Document Type: Article

References (37)

1. Stewart BW, Wild CP, eds. World Cancer Report 2014. Lyon, France: International Agency for Research on Cancer; 2014.
2. Ellis PM, Coakley N, Feld R, et al. Use of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the treatment of non-small-cell lung cancer: A systematic review. Curr Oncol. 2015; 22: e183-e215.
3. Dempke WC, Suto T, Reck M. Targeted therapies for nonsmall cell lung cancer. Lung Cancer. 2010; 67: 257-274.
4. Gridelli C, Peters S, Sgambato A, et al. ALK inhibitors in the treatment of advanced NSCLC. Cancer Treat Rev. 2014; 40: 300-306.
5. Kohno T, Ichikawa H, Totoki Y, et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med. 2012; 18: 375-377.
6. Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol. 2012; 30: 2046-2054.
7. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015; 373: 123-135.
8. Carbone DP, Gandara DR, Antonia SJ, et al. Non-smallcell lung cancer: role of the immune system and potential for immunotherapy. J Thorac Oncol. 2015; 10: 974-984.
9. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366: 2455-2465.
10. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015; 372: 2018-2028.
11. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015; 348: 69-74.
12. Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014; 371: 2189-2199.
13. Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348: 124-128.
14. Sharma P, Wagner K, Wolchok JD, et al. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Review Cancer. 2011; 11: 805-812.
15. Gilboa E. The makings of a tumor rejection antigen. Immunity. 1999; 11: 263-270.
16. Segal NH, Parsons DW, Peggs KS, et al. Epitope landscape in breast and colorectal cancer. Cancer Res. 2008; 68: 889-892.
17. Matsushita H, Vesely MD, Koboldt DC, et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature. 2012; 482: 400-404.
18. Kreiter S, Vormehr M, van de Roemer N, et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature. 2015; 520: 692-696.
19. Carreno BM, Magrini V, Becker-Hapak M, et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science. 2015; 348: 803-808.
20. Overwijk WW, Wang E, Marincola FM, et al. Mining the mutanome: developing highly personalized Immunotherapies based on mutational analysis of tumors. J Immunother Cancer. 2013; 1: 11.
21. Forbes SA, Beare D, Gunasekaran P, et al. COSMIC: exploring the worlds knowledge of somatic mutations in human cancer. Nucleic Acids Res. 2015; 43: D805-D811.
22. Nielsen M, Lundegaard C, Blicher T, et al. NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and-B locus protein of known sequence. PLoS One. 2007; 2: e796.
23. Hoof I, Peters B, Sidney J, et al. NetMHCpan, a method for MHC class I binding prediction beyond humans. Immunogenetics. 2009; 61: 1-13.
24. Sette A, Vitiello A, Reherman B, et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol. 1994; 153: 5586-5592.
25. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009; 25: 1754-1760.
26. Koboldt DC, Zhang Q, Larson DE, et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 2012; 22: 568-576.
27. Cibulskis K, Lawrence MS, Carter SL, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013; 31: 213-219.
28. McKenna A, Hanna M, Banks E, et al. The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010; 20: 1297-1303.
29. Major E, Rigó K, Hague T, et al. HLA Typing from 1000 Genomes Whole Genome and Whole Exome Illumina Data. PLoS One. 2013; 8: e78410.
30. Immune Epitope Database and Analysis Resource. http: //www.iedb.org. Accessed August 3, 2015.
31. Ong M, Carreira S, Goodall J, et al. Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail. Br J Cancer. 2014; 111: 828-836.
32. Hovelson DH, McDaniel AS, Cani AK, et al. Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors. Neoplasia. 2015; 17: 385-399.
33. The Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012; 489: 519-525.
34. Nielsen M, Lundegaard C, Lund O, et al. The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage. Immunogenetics. 2005; 57: 33-41.
35. Saxova P, Buus S, Brunak S, et al. Predicting proteasomal cleavage sites: A comparison of available methods. Int Immunol. 2003; 15: 781-787.
36. Kesmir C, Nussbaum AK, Schild H, et al. Prediction of proteasome cleavage motifs by neural networks. Protein Eng. 2002; 15: 287-296.
37. Stranzl T, Larsen MV, Lundegaard C, et al. NetCTLpan: pan-specific MHC class I pathway epitope predictions. Immunogenetics. 2010; 62: 357-368.